



30th November 2016

## BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
<b>Indices</b>			
Dow Jones	19121.6	+0.12%	+9.74%
S&P 500	2204.66	+0.13%	+7.86%
Nasdaq	5379.92	+0.21%	+7.44%
Nikkei	18308.48	+0.01%	-3.82%
Stoxx 600	340.946	+0.33%	-6.80%
CAC 40	4551.46	+0.91%	-1.85%
<b>Oil /Gold</b>			
Crude WTI	45.23	-3.93%	+21.59%
Gold (once)	1185.88	-0.50%	+11.62%
<b>Currencies/Rates</b>			
EUR/USD	1.06195	+0.33%	-2.24%
EUR/CHF	1.0768	+0.25%	-0.97%
German 10 years	0.146	+35.66%	-76.96%
French 10 years	0.712	-7.33%	-27.46%

### Economic releases :

Date	
30th-Nov	13h30 draghi speaks in Madrid 16h00 OPEC Press Conference 16h30 US - DoE Inventories 08h00 - GB BoE Publishes financial stability report 8h00 - German Retail Sales Oct. (+1.0% y/y) 09h55 DE Unemployment rate Nov. (0.6% E)


### Upcoming BG events :

Date	
30th-Nov	VALEO (BG Lunch with IR)
5th-Dec	Reverse roadshow in Paris / Construction
5th-Dec/ 6th-Dec	ATOS (BG Paris Roadshow CFO & IR)
8th-Dec	Reverse roadshow Brewers Netherlands, Belgium
12th-Dec	Jean-Pierre Petit, Président des Cahiers Verts de l'Economie.
13th-Dec	Jean-Pierre Petit, Président des Cahiers Verts de l'Economie.

### Recent reports :

Date	
29th-Nov	Morphosys We want MORE! (Fair Value EUR65 BUY)
28th-Nov	Fashion E-Commerce: Serving Consumers not Uberising Them! Coverage initiation of ZALANDO, YOOX, H&M,
25th-Nov	Brewers
23rd-Nov	SPIRITS : Rising to the Generation Y challenge
22nd-Nov	ORPEA More than ever a BUY
21st-Nov	Innate - Still time to jump on the bandwagon

List of our Reco & Fair Value : Please click here to download



### INDRA SISTEMAS

**BUY vs. NEUTRAL, Fair Value EUR12 (+24%)**

*Tecnocom acquisition conference call feedback: a defensive move, synergies ahead*

We raise our recommendation from Neutral to Buy following the conference call held yesterday for the acquisition of Tecnocom for EUR305m in cash and shares. At first glance, this tie-up may cause scepticism as it looks like a defensive move. However, if the EUR41m in projected synergies is successfully implemented, based on a strong overlap between the two companies in Spain and LatAm, we consider it could enhance adj. EPS by 3% in 2017, 9% in 2018, and 10%+ beyond.

### SAGE GROUP

**SELL, Fair Value 690p (+2%)**

*FY16 results in line with our expectations, FY17 outlook in line with FY16*

This morning Sage reported FY16 results in line with our estimates and slightly above consensus. Following a 12% rise during the last 6 months due to strong fx tailwinds, we expect the share price not to react significantly in short term.

### In brief...

**ABLYNX, First milestone reached in Novo Nordisk's collaboration**

**NOVO NORDISK, Full DEVOTE results now available**

**STMICROELECTRONICS, ST rumoured to have signed a contract with Apple to supply the next gen of image sensor**

## TMT

## Indra Sistemas

Price EUR9.69

Tecnocom acquisition conference call feedback: a defensive move, synergies ahead

Fair Value EUR12 (+24%)

BUY vs. NEUTRAL

Bloomberg	IDR SM
Reuters	IDR.MC
12-month High / Low (EUR)	12.3 / 7.7
Market Cap (EUR)	1,590
Ev (BG Estimates) (EUR)	2,287
Avg. 6m daily volume (000)	772.0
3y EPS CAGR	

	1 M	3 M	6 M	31/12/15
Absolute perf.	-14.2%	-16.4%	-5.3%	11.8%
Softw. & Comp.	-1.2%	-1.3%	3.7%	3.3%
DJ Stoxx 600	0.0%	-0.7%	-2.5%	-6.8%

YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	2,850	2,738	2,813	2,920
% change		-3.9%	2.7%	3.8%
EBITDA	107	218	307	372
EBIT	-641.0	155.0	236.0	297.0
% change		NS	52.3%	25.8%
Net income	-73.0	84.0	150.0	196.0
% change		NS	78.6%	30.7%

	2015	2016e	2017e	2018e
Operating margin	1.6	5.7	8.4	10.2
Net margin	-22.5	2.9	5.2	6.6
ROE	-208.1	20.7	27.6	26.4
ROCE	-11.7	11.3	17.7	22.0
Gearing	227.0	181.0	98.0	41.0

(€)	2015	2016e	2017e	2018e
EPS	-0.40	0.44	0.78	1.02
% change	-	NS	77.3%	30.8%
P/E	NS	22.0x	12.4x	9.5x
FCF yield (%)	NM	0.6%	9.4%	12.0%
Dividends (€)	0.00	0.00	0.00	0.00
Div yield (%)	NM	NM	NM	NM
EV/Sales	0.8x	0.8x	0.8x	0.6x
EV/EBITDA	21.4x	10.5x	6.9x	5.1x
EV/EBIT	49.8x	14.8x	9.0x	6.4x

**We raise our recommendation from Neutral to Buy following the conference call held yesterday for the acquisition of Tecnocom for EUR305m in cash and shares. At first glance, this tie-up may cause scepticism as it looks like a defensive move. However, if the EUR41m in projected synergies is successfully implemented, based on a strong overlap between the two companies in Spain and LatAm, we consider it could enhance adj. EPS by 3% in 2017, 9% in 2018, and 10%+ beyond.**

## ANALYSIS

**A tale of economies of scale.** For Indra, the rationale behind the acquisition of Tecnocom is essentially the need for economies of scale. With Tecnocom, Indra will increase revenues in Spain by 39% and will be the clear leader in its domestic IT Services market with 38% more revenues than the No. 2 Accenture (EUR1,136m vs. EUR823m based on 2015 revenues, while it was at EUR819m). This would result in significant operating leverage on fixed costs due to a strong overlap not only in Spain (80% of sales and staff) and LatAm. In addition, Tecnocom teams would benefit from Indra's delivery model including offshoring. Indra would increase revenue exposure to Financial Services to 34% from 30% - with complementary offerings (Indra in Core Banking and Core Insurance, Tecnocom in Payment Systems) - and the commercial sector in Spain (78% of revenues vs. 75%). As the top 5 players in Spain (Indra, Accenture, Ibermatica, Everis, Tecnocom) have a combined 30% market share in IT Services, an issue with antitrust authorities is unlikely.

**Significant synergies ahead.** Indra expects to deliver EUR41m in synergies within two years. This includes EUR10.5m in revenue synergies (upselling, cross-selling especially in Financial Services, Industry and Utilities) and EUR30.5m in cost synergies (potential SG&A optimisation through sales and overhead costs, higher production efficiency and enhancement of the operating model on utilisation rates, the salary pyramid, offshore leverage, facilities rationalisation, optimisation of R&D efforts and capex). The deal is expected to close in April or May 2017 and management expects that 50% of these synergies to be effective in year 1 and the other 50% in year 2, while 75% of the costs (restructurings, integration, etc.: 2x the amount expected for cost synergies, i.e. an est. EUR60m) will be spent in year 1 and the remaining 25% in year 2. Management estimates the NPV of synergies at EUR306m including a WACC of 9%.

**Potential double-digit EPS accretion.** The acquisition of Tecnocom is expected to add free cash flow on top of the EUR200m guided for Indra by 2018. The net debt/EBITDA ratio is expected to worsen by only 0.2-0.3x by end 2018, but the effect will be stronger at end-2017. The capital increase for the share exchange offer (40% of the acquisition price) is expected to create 12.4m new Indra shares and then generate a 7% initial dilution (6% on a fully diluted basis incl. convertible bonds). Finally, Indra's op. margin target for 2018 (10-11%) is unchanged if we take into account the synergies it would derive from Tecnocom. At first glance, taking into account the implementation of synergies and associated costs from May 2017 (cost synergies: est. EUR9m for 2017 and est. EUR24m for 2018; restructuring costs: est. EUR46m for 2017 and est. EUR16m for 2018), and Tecnocom's 2018 goals (sales CAGR 7.5-10% for 2015-2018, EBITDA margin 7.5-8.5% in 2018 implying an est. EBIT margin of 5-6%), we expect Tecnocom to have a slight negative impact on our current op. margin ests. (-0.2ppt for 2017 to 8.2% and -0.1ppt for 2018 to 10.1%) and be accretive to our current adj. EPS ests. (est. +3% for 2017, est. +9% for 2018, 10%+ beyond).

## VALUATION

Indra's shares are trading at est. 14.8x 2016 and 9.0x 2017 EV/EBIT multiples.

Net debt on 30th September 2016 was EUR666.4m (net gearing: 187%).

## NEXT CATALYSTS

FY16 results in February 2017.

[Click here to download](#)



**Analyst :**  
Gregory Ramirez  
33(0) 1 56 68 75 91  
gramirez@bryangarnier.com

**Sector Team :**  
Richard-Maxime Beaudoux  
Thomas Coudry  
Dorian Terral

TMT

**Sage Group**

Price 675.50p

FY16 results in line with our expectations, FY17 outlook in line with FY16

Fair Value 690p (+2%)

SELL

This morning Sage reported FY16 results in line with our estimates and slightly above consensus. Following a 12% rise during the last 6 months due to strong fx tailwinds, we expect the share price not to react significantly in short term.

**ANALYSIS**

- FY16 results in line with our expectations.** For FY16, Sage reported sales up 9.3% to GBP1,569.1m (+6.1% lfl), an adj. operating profit up 12.4% to GBP427m or 27.2% of sales (vs. 26.5% for FY15), an EBIT up 1.1% to GBP300.4m after GBP107.7m non-recurring costs, a net profit up 6.8% to GBP207.6m, and an adj. EPS up 9% to 27.8p. We expected revenues up 6.3% lfl to GBP1,576m (consensus: GBP1,561m), an adj. operating profit of GBP427.5m of 27.1% of sales (consensus: GBP420m or 26.9% of sales), and an adj. EPS of 27.6p (consensus: 27.5p), while the management guided on revenues up at least 6% lfl and an organic operating margin of at least 27%. Recurring revenues (70% of sales) were up 10.4% lfl, processing revenues (13%) were up 6.1% lfl, and SSRS (Software/software-related services, 17%) revenues were down 8.5% lfl. Free cash flow was GBP254m, and underlying cash conversion was 100% vs. 106% for FY15. Finally, the total ordinary dividend proposed for FY16 is 14.15p per share (+8%).

- More details on the figures.** 1). Europe: sales +6.6% lfl to GBP827m (+7% in the UK, +6% in France, +7% in Germany, +7% in Spain, +3% on Rest of Europe), with Recurring up 10.2% lfl, Processing up 11.5% and SSRS down 7.4% lfl, for a 30.9% EBITA margin (vs. 29.8% in FY15); 2). North America: sales +4.4% lfl to GBP535.5m, with Recurring up 8.5% lfl, Processing up 2.9% lfl and SSRS down 7.6% lfl, for an EBITA margin of 25.1% (vs. 22.9% in FY15); 3). International: sales +8.4% lfl to GBP206.6m (+19% in Africa, +12% in Brazil, +3% in Australia, -18% in Middle East & Asia), with Recurring up 16% lfl, Processing up 49.8% and SSRS down 12.4% lfl, for an EBITA margin of 17.9% (vs. 26.5% in FY15). Subscription contracts rose by 46%. Sage X3 ERP sales were up 18%, subscriptions for Sage One reached 313,000 paying subscribers (vs. 173,000 one year ago and 230,000 6 months ago) with revenues up 54%, Sage Live has 600 customers (o/w 400 in the last 90 days), and Sage 50 Accounts subscription sales were up triple-digit in the UK, the US and Canada.

- Unchanged outlook.** Sage has achieved the first phase of its transformation programme and now enters phase 2, which will continue to be non-linear and focus on more technology innovation with increasing focus on new customer acquisition and continuing to improve execution. Annualised cost savings reached GBP51m in FY16 for a cost of GBP110m (o/w GBP76m in G&A). For FY17, the management forecasts at least 6% lfl revenue growth and at least 27% organic operating margin. Investments in growth will be front-loaded in H1 FY17, while H2 is anticipated to generate stronger growth and accelerating momentum. In other words, the operating margin will be below 27% in H1 and above 27% in H2. FY17 annualised cost savings are expected to reach at least GBP50m, as initially stated. We forecast for FY17 sales up 6.5% lfl to GBP1,889m (consensus: GBP1,773m) and an adj. EBITA margin of 27.6% (consensus: 27%).

**VALUATION**

- Sage's shares are trading at est. 17.0x FY16, 13.4x FY17 and 11.7x FY18 EV/EBIT multiples.
- Net debt on 30<sup>th</sup> September 2016 was GBP397m (net gearing: 38%).

**NEXT CATALYSTS**

Analysts' meeting at 8.30am BST / 9.30am CET / 3.30am EDT in London (London Stock Exchange, 10 Paternoster Square) or call +44 20 34 27 19 13.

[Click here to download](#)

Bloomberg	SGE L
Reuters	SGE LN
12-month High / Low (p)	756.0 / 544.5
Market Cap (GBPm)	7,296
Ev (BG Estimates) (GBPm)	7,425
Avg. 6m daily volume (000)	2 603
3y EPS CAGR	13.3%

	1 M	3 M	6 M	31/12/15
Absolute perf.	-6.4%	-7.3%	11.7%	11.9%
Softw. & Comp.	-1.2%	-1.3%	3.7%	3.3%
DJ Stoxx 600	0.0%	-0.7%	-2.5%	-6.8%

YEnd Sept. (£m)	09/15	09/16e	09/17e	09/18e
Sales	1,436	1,576	1,889	2,028
% change		9.8%	19.8%	7.3%
EBITDA	418	461	554	606
EBIT	297.2	314.7	503.9	555.9
% change		5.9%	60.1%	10.3%
Net income	286.7	310.6	383.5	423.6
% change		8.3%	23.5%	10.5%

	09/15	09/16e	09/17e	09/18e
Operating margin	27.1	27.8	28.1	28.7
Net margin	13.5	13.7	18.9	19.6
ROE	22.5	23.5	32.3	30.1
ROCE	25.2	33.8	42.5	49.9
Gearing	39.6	14.1	-15.8	-34.1

(p)	09/15	09/16e	09/17e	09/18e
EPS	25.59	27.57	33.86	37.23
% change	-	7.7%	22.8%	9.9%
P/E	26.4x	24.5x	19.9x	18.1x
FCF yield (%)	3.9%	4.6%	6.2%	6.0%
Dividends (p)	13.10	14.15	15.28	16.50
Div yield (%)	1.9%	2.1%	2.3%	2.4%
EV/Sales	5.3x	4.7x	3.8x	3.4x
EV/EBITDA	18.3x	16.1x	12.8x	11.3x
EV/EBIT	19.6x	17.0x	13.4x	11.7x



**Analyst :**  
 Gregory Ramirez  
 33(0) 1 56 68 75 91  
[gramirez@bryangarnier.com](mailto:gramirez@bryangarnier.com)

**Sector Team :**  
 Richard-Maxime Beaudoux  
 Thomas Coudry  
 Dorian Terral

## Healthcare

**Ablynx**

Price EUR9.19

**First milestone reached in Novo Nordisk's collaboration**

Fair Value EUR16 (+74%)

BUY

Bloomberg	ABLX.BB
Reuters	ABLX.BR
12-month High / Low (EUR)	16.1 / 8.4
Market Cap (EURm)	560
Avg. 6m daily volume (000)	217.0

	1 M	3 M	6 M	31/12/15
Absolute perf.	1.7%	-21.3%	-35.3%	-42.2%
Healthcare	0.8%	-6.4%	-8.8%	-13.9%
DJ Stoxx 600	0.0%	-0.7%	-2.5%	-6.8%

	2015	2016e	2017e	2018e
P/E	NS	NS	NS	NS
Div yield (%)	NM	NM	NM	NM

**ANALYSIS**

- Ablynx has achieved a EUR1m discovery milestone as part of its collaboration with Novo Nordisk. We are pleased with the rapid development of the collaboration, this milestone being paid one year after the deal was inked on 25th November 2015. As a reminder, Ablynx was paid EUR5m upfront, EUR4m in research funding over three years and is eligible for regulatory and commercial milestones of up to EUR182m.
- As Ablynx' preclinical collaboration deals are constructed, we are not ruling out the possibility that this milestone could mean that the multi-specific Nanobody is at least as good as a combination of two compounds. This bodes well for the development of the Nanobody in clinical studies in 2018. With Novo Nordisk having intensive R&D activities in diabetes and haemophilia, we are not ruling out the possibility of these areas falling under the discovery programme. Note also that as part of the agreement, the big pharma has the option to expand the discovery agreement to a second Nanobody programme.

**VALUATION**

- We reiterate our BUY recommendation and EUR16 Fair Value.
- This news does not impact our estimates as we would wait for the therapeutic targets to be disclosed to subsequently include any milestones.

**NEXT CATALYSTS**

- H1 2017:
  - Two INDs to be filed to the FDA for I-O candidate within the Merck&Co partnership,
  - ALX-0761 in psoriasis, presentation of phase Ib by Merck KGaA.
- H2 2017:
  - Caplacizumab in aTTP, results from HERCULES phase III trial,
  - Initiation of phase III for vobarilizumab in RA upon new partnership agreement.

[Click here to download](#)[Hugo Solvet, hsolvet@bryangarnier.com](mailto:Hugo.Solvet,hsolvet@bryangarnier.com)

Healthcare

**Novo Nordisk**

Price DKK230.10

Full DEVOTE results now available

Fair Value DKK270 (+17%)

NEUTRAL

Bloomberg	NOVOB.DC
Reuters	NOVOB.CO
12-month High / Low (DKK)	404.2 / 220.7
Market Cap (DKKm)	463,091
Avg. 6m daily volume (000)	3 670

	1 M	3 M	6 M	31/12/15
Absolute perf.	-3.1%	-26.5%	-38.0%	-42.5%
Healthcare	0.8%	-6.4%	-8.8%	-13.9%
DJ Stoxx 600	0.0%	-0.7%	-2.5%	-6.8%

	2015	2016e	2017e	2018e
P/E	17.0x	15.2x	14.9x	14.2x
Div yield (%)	2.8%	3.0%	3.0%	3.2%

**ANALYSIS**

In March 2015, the company decided to resubmit the NDA of Tresiba (and Ryzodeg) in the US in the form of a class II resubmission that included pre-specified interim data from the cv outcome trial DEVOTE. DEVOTE was initiated in October 2013 and the required number of events was reached in January 2015 to carry out an interim analysis based on MACE, thus answering the initial question about a potential concern with the cardiovascular safety profile of the drug.

Yesterday, Novo-Nordisk reported the final results of the study which compared Tresiba to Lantus on top of standard of care. More than 7,500 patients were treated for approximately two years. The study achieved its primary endpoint and Tresiba was therefore deemed as non-inferior to Lantus by the number of cv events computed during the treatment period (cv death, non-fatal MI, non-fatal stroke). The trial also showed a similar reduction of HbA1c in the populations treated with the two drugs. Lastly, the trial also reached its secondary endpoints and Tresiba demonstrated superiority over Lantus in reducing the risk of severe hypoglycemic events (-40%), the number of patients experiencing at least one episode (-27%) and the incidence of nocturnal severe episodes (-54%). Novo expects to file in H1 2017 and to get a claim in the label of Tresiba.

We are obviously in an environment where minor improvements are no longer well rewarded when the price to pay is too high. Gargine U100 is available in Europe at a discount price already and Basaglar is coming soon in the US. Equivalence on cv outcomes data AND HbA1c reduction does not make life easy for Tresiba. Let's see how much it differs from Lantus on hypoglycaemia in absolute terms (likely at ADA 2017) and if there is evidence that the rate of severe hypos is predictive of the incidence of MACE.

**VALUATION**

No change.

**NEXT CATALYSTS**

Today 8am: Conference Call on DEVOTE - [Click here to download](#)

Eric Le Berrigaud, [eleberrigaud@bryangarnier.com](mailto:eleberrigaud@bryangarnier.com)

TMT

**STMicroelectronics**

Price EUR9.31

ST rumoured to have signed a contract with Apple to supply the next gen of image sensor

Fair Value EUR7.3 (-22%)

NEUTRAL

Bloomberg	STM.FP
Reuters	STM.FR
12-month High / Low (EUR)	9.4 / 4.6
Market Cap (EURm)	8,482
Avg. 6m daily volume (000)	2,272

	1 M	3 M	6 M	31/12/15
Absolute perf.	10.4%	38.0%	71.5%	50.6%
Semiconductors	1.6%	6.9%	27.3%	27.3%
DJ Stoxx 600	0.0%	-0.7%	-2.5%	-6.8%

	2015	2016e	2017e	2018e
P/E	50.0x	34.7x	22.2x	16.0x
Div yield (%)	4.3%	3.2%	3.2%	4.3%

**ANALYSIS**

**According to Challenges, STMicroelectronics will manufacture the next generation of image sensors for Apple.** According to the French newspaper, the image sensors would be produced at Crolles. Note that Crolles 300mm (Crolles 2) is currently the most advanced production capability at ST (28nm FD-SOI). It is also running at a low utilisation rate, i.e. south of 70% in Q3 2016, and has a significant impact on the group's margin due to related unused costs (for the fourth quarter, the group expects to see a negative impact of 20bps from unused charges). As such, this contract with Apple could have a positive impact on ST's margin. In addition, Challenges also provides components to SpaceX, the aerospace manufacturer created by Elon Musk.

**Note that in June, [we already highlighted](#) a rumour about Apple opening an R&D center next to ST offices in Grenoble to work on next generation camera image sensors.** This new rumour goes one step further talking about manufacturing at Crolles 300. However, the impact on sales might vary significantly, depending on what type of co-development ST and Apple are thinking of (IP, R&D, co-development manufacturing only, etc.) and also what type of image sensor. Indeed, it also could be assistance systems such as optical image stabilisation + autofocus systems next to an Apple proprietary image sensor or a full system including the image sensor and new features such as enhanced depth of field thanks to the addition of Time of Flight sensors.

**VALUATION**

Based on our estimates, STMicroelectronics' shares are trading on 2017e EV/Sales and EV/EBIT ratios of 1.1x and 17.4x respectively.

**NEXT CATALYSTS**

Late January 2017: FY16 and Q4 results (not confirmed yet).

[Click here to download](#)

Dorian Terral, dterral@bryangarnier.com

## BG's Wake Up Call

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

### Distribution of stock ratings

BUY ratings 55.1%

NEUTRAL ratings 33.5%

SELL ratings 11.4%

## Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/Infrastructures/Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Automotive & Parts		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

London	Paris	New York	Munich
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudentiel et de résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany <b>+49 89 2422 62 11</b>



## BRYAN, GARNIER & Co

### Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

### Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

#### Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

#### Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

#### Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

#### Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....